# RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer

> **NCT07732634** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Illinois at Chicago** · enrollment: 20 (estimated)

## Conditions studied

- Head and Neck Cancer
- Head Cancer
- Neck Cancer

## Interventions

- **DRUG:** RiMO-301
- **DRUG:** Pembrolizumab
- **RADIATION:** Radiation
- **PROCEDURE:** Surgical resection

## Key facts

- **NCT ID:** NCT07732634
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2029-08
- **Final completion:** 2031-08
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07732634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07732634, "RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07732634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*